This is a non-core endpoint: only basic statistics are computed.
Follow-up examination after treatment for conditions other than malignant neoplasms
Z21_FOLLOW__EXAM_TREAT_CONDI_OTH_MALIG_NEOPLASMS
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
25146
Check minimum number of events None
25146
Include endpoints None
25146
Remove individuals based on genotype QC
24333
Z21_FOLLOW__EXAM_TREAT_CONDI_OTH_MALIG_NEOPLASMS
Control definitions
Control exclude
Z21_PERSONS_ENCOUNTERI_HEALTH_SERVI_EXAM_INVES
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Z[0-1]
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Follow-up examination after treatment for conditions other than malignant neoplasms
based on the number of shared cases.
Broader endpoints:
- Persons encountering health services for examination and investigation
- Factors influencing health status and contact with health services
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 24333 | 19738 | 4595 |
| Unadjusted prevalence (%) | 6.45 | 9.36 | 2.76 |
| Mean age at first event (years) | 49.77 | 48.37 | 55.80 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: Z21_FOLLOW__EXAM_TREAT_CONDI_OTH_MALIG_NEOPLASMS – Follow-up examination after treatment for conditions other than malignant neoplasms
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Follow-up examination after treatment for conditions other than malignant neoplasms
↥Endpoint not on priority list, no data to show.